GLP-1 beginner tips on TikTok: What holds up under scrutiny?

What's this video probably claiming?

Based on the caption and hashtags, this video is almost certainly a listicle-style guide aimed at people just starting semaglutide or tirzepatide. Creators in this space typically cover the usual suspects: start low and go slow on doses, manage nausea with bland foods, stay hydrated, eat protein to preserve muscle, and don't panic if the scale stalls. There's also a reasonable chance the video touches on injection timing, what to do on shot day, or how to handle side effects like constipation and fatigue. These are genuinely useful topics. The problem is that TikTok's format rewards confidence over nuance, and beginner-tip videos often collapse important clinical distinctions into bite-sized rules that sound authoritative but strip out the caveats that actually matter in practice.

What does the science actually show?

The clinical data on GLP-1 receptor agonists is legitimately strong. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean weight loss of 20.9% over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% weight loss over 68 weeks. Both drugs work by slowing gastric emptying and suppressing appetite through incretin pathways, with tirzepatide also acting on GIP receptors. What the studies also show, and what TikTok rarely mentions, is that roughly 10-15% of trial participants discontinued due to GI adverse events. Muscle loss is a real concern too. A 2023 analysis by Bikou et al. in Nutrients found lean mass losses of 25-39% of total weight lost, depending on protein intake and activity level.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 culture and clinical reality is wide in a few specific areas. First, the protein obsession. Eating 100-150g of protein daily is repeated constantly online as a near-magical fix for muscle loss, but the evidence that protein alone offsets GLP-1-associated lean mass loss without resistance training is not strong. Second, the nausea tips. Ginger tea and bland crackers get promoted like they're evidence-based interventions. They're not. They're reasonable comfort measures, but uncontrolled nausea that persists beyond the first week of a new dose should be a clinical conversation, not a TikTok comment thread. Third, dose timing myths circulate heavily. Claims that injecting on a specific day of the week or at a specific time of day meaningfully changes efficacy or side effects are largely unsupported. The pharmacokinetics of weekly semaglutide show a half-life of approximately 7 days, meaning consistency matters more than timing.

What should you actually know?

If you're starting a GLP-1 medication, the most evidence-supported advice is also the least exciting. The slow titration schedules built into these medications exist for a reason. Semaglutide typically starts at 0.25mg weekly for 4 weeks before any increase. Tirzepatide starts at 2.5mg. Rushing titration is the most common self-reported reason for early discontinuation due to side effects. Resistance training data is more compelling than any dietary tip for preserving lean mass. A 2023 randomized trial (Lundgren et al., Obesity) showed that combining semaglutide with resistance training preserved significantly more lean mass than drug alone. Finally, GLP-1 medications require ongoing medical supervision. Gallstone formation, pancreatitis risk in certain populations, and drug interactions are real clinical considerations that beginner tip videos don't cover and can't adequately substitute for a proper consultation.